Lipocine Inc. (Nasdaq: LPCN),
a specialty pharmaceutical company, today announced positive top-line results
from a Phase 2a clinical study of LPCN 1111, a novel testosterone replacement
therapy ("TRT") candidate, in hypogonadal males. The...
By Jason Napodano, CFA:
On September 17th, there was a Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (OTC:DSRM) to examine the appropriate...
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Repros+Therapeutics+%28RPRX%29+Reports+Results+of+FDA+Panel+TRT+Meeting%3B+Population+Not+Suited+to+Androxal/9849970.html for the full story.
By David Bautz:
On September 17, 2014, the FDA will hold a joint meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss testosterone replacement therapy (TRT)....
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.